ACRS($782M) has a higher market cap than BCYC($271M). ACRS YTD gains are higher at: 76.744 vs. BCYC (-45.480). ACRS has higher annual earnings (EBITDA): -85.09M vs. BCYC (-183.2M). BCYC has more cash in the bank: 510M vs. ACRS (91.6M). BCYC has higher revenues than ACRS: BCYC (61.2M) vs ACRS (8.22M).

	ACRS	BCYC	ACRS / BCYC
Capitalization	782M	271M	289%
EBITDA	-85.09M	-183.2M	46%
Gain YTD	76.744	-45.480	-169%
P/E Ratio	N/A	N/A	-
Revenue	8.22M	61.2M	13%
Total Cash	91.6M	510M	18%
Total Debt	N/A	14.7M	-

FUNDAMENTALS RATINGS

ACRS vs BCYC: Fundamental Ratings

	ACRS	BCYC
OUTLOOK RATING 1..100	73	56
VALUATION overvalued / fair valued / undervalued 1..100	47 Fair valued	9 Undervalued
PROFIT vs RISK RATING 1..100	100	100
SMR RATING 1..100	98	97
PRICE GROWTH RATING 1..100	36	74
P/E GROWTH RATING 1..100	100	100
SEASONALITY SCORE 1..100	31	n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (9) in the null industry is somewhat better than the same rating for ACRS (47) in the Pharmaceuticals Other industry. This means that BCYC’s stock grew somewhat faster than ACRS’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as ACRS (100) in the Pharmaceuticals Other industry. This means that BCYC’s stock grew similarly to ACRS’s over the last 12 months.

BCYC's SMR Rating (97) in the null industry is in the same range as ACRS (98) in the Pharmaceuticals Other industry. This means that BCYC’s stock grew similarly to ACRS’s over the last 12 months.

ACRS's Price Growth Rating (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for BCYC (74) in the null industry. This means that ACRS’s stock grew somewhat faster than BCYC’s over the last 12 months.

ACRS's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as BCYC (100) in the null industry. This means that ACRS’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS

Technical Analysis

	ACRS	BCYC
RSI ODDS (%)	5 days ago 71%	N/A
Stochastic ODDS (%)	2 days ago 81%	2 days ago 82%
Momentum ODDS (%)	2 days ago 82%	2 days ago 90%
MACD ODDS (%)	2 days ago 77%	2 days ago 90%
TrendWeek ODDS (%)	2 days ago 81%	2 days ago 87%
TrendMonth ODDS (%)	2 days ago 77%	2 days ago 86%
Advances ODDS (%)	26 days ago 83%	23 days ago 78%
Declines ODDS (%)	2 days ago 84%	3 days ago 89%
BollingerBands ODDS (%)	2 days ago 90%	2 days ago 85%
Aroon ODDS (%)	2 days ago 85%	2 days ago 87%

COMPARISON

Comparison

Sep 12, 2026

Stock price -- (ACRS: $5.32 vs. BCYC: $3.86)

Brand notoriety: ACRS and BCYC are both not notable

Both companies represent the Biotechnology industry

Current volume relative to the 65-day Moving Average: ACRS: 175% vs. BCYC: 213%

Market capitalization -- ACRS: $782.36M vs. BCYC: $270.87M

ACRS [@Biotechnology] is valued at $782.36M. BCYC’s [@Biotechnology] market capitalization is $270.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACRS’s FA Score shows that 0 FA rating(s) are green while BCYC’s FA Score has 1 green FA rating(s).

ACRS’s FA Score: 0 green, 5 red.
BCYC’s FA Score: 1 green, 4 red.

According to our system of comparison, ACRS is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACRS’s TA Score shows that 4 TA indicator(s) are bullish while BCYC’s TA Score has 4 bullish TA indicator(s).

ACRS’s TA Score: 4 bullish, 5 bearish.
BCYC’s TA Score: 4 bullish, 5 bearish.

According to our system of comparison, both ACRS and BCYC are a bad buy in the short-term.

Price Growth

ACRS (@Biotechnology) experienced а -13.78% price change this week, while BCYC (@Biotechnology) price change was -10.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

ACRS is expected to report earnings on Nov 11, 2026.

BCYC is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three

ACRS

Daily Signal:

Gain/Loss:

BCYC

Setup

Daily Signal:

Description

Gain/Loss:

Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)

VIEW DETAILS VIEW DETAILS

VIEW FOR FREE VIEW FOR FREE

Interact to see
Advertisement

Interesting Tickers

MFs / NAME	Price $	Chg $	Chg %
		1 Day
CDGIX	15.17	N/A	N/A
Crawford Large Cap Dividend I
IWEDX	15.23	N/A	N/A
Voya Large Cap Value W
CNSIX	28.10	N/A	N/A
Invesco Convertible Securities R5
BRSSX	16.64	N/A	N/A
MFS Blended Research Small Cap Eq R2
FIOOX	22.12	N/A	N/A
Fidelity Series Large Cap Value Index

ACRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACRS has been closely correlated with CRVS. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACRS jumps, then CRVS could also see price increases.

Ticker / NAME	Correlation To ACRS	1D Price Change %
ACRS	100%	-3.36%
CRVS - ACRS	67% Closely correlated	-0.23%
STRRP - ACRS	52% Loosely correlated	+0.10%
QUCY - ACRS	40% Loosely correlated	-2.19%
UFPT - ACRS	39% Loosely correlated	+0.18%
BCYC - ACRS	37% Loosely correlated	+0.78%
More

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with DNLI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then DNLI could also see price increases.

Ticker / NAME	Correlation To BCYC	1D Price Change %
BCYC	100%	+0.78%
DNLI - BCYC	48% Loosely correlated	-1.45%
PCVX - BCYC	48% Loosely correlated	+0.97%
MGTX - BCYC	47% Loosely correlated	-0.47%
BHVN - BCYC	46% Loosely correlated	-0.63%
NGNE - BCYC	46% Loosely correlated	-1.77%
More